Compare PRT & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRT | FEMY |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 37.2M |
| IPO Year | N/A | 2021 |
| Metric | PRT | FEMY |
|---|---|---|
| Price | $2.95 | $0.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 52.3K | ★ 577.6K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 12.70% | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | N/A | $183.83 |
| Revenue Next Year | N/A | $196.80 |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $2.61 | $0.31 |
| 52 Week High | $4.28 | $1.29 |
| Indicator | PRT | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 35.38 | 40.76 |
| Support Level | N/A | $0.33 |
| Resistance Level | $3.57 | $0.58 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 8.41 | 45.56 |
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.